The Effect Of Treatment With Alpha-Glycosidases From Bacteroides Fragilis On The Survival Of Rat Erythrocytes In The Circulation

Background. It has been demonstrated recently that alpha 1,3-galactosidase from Bacteroides fragilis can efficiently convert human group B red blood cells (RBC) to group O cells. In addition, in vitro data indicated that the enzymatic conversion process did not affect the physiological or metabolic parameters of the RBC. The aim of this study was to investigate the lifespan of enzyme- treated RBC in vivo in the circulation.Materials and methods. This was an experimental, randomised study. The rat was selected as the experimental subject because it expresses alpha-1,3galactosyl on its RBC. The efficiency of Gal alpha 1,3Gal epitope removal from RBC treated with alpha 1,3-galactosidase was tested before the transfusion experiment to track the survival of RBC in the circulation. The animals were divided into three groups and injected via the tail vein with native, mock-treated or enzyme-treated RBC labelled with fluorescein isothiocyanate. The survival rates of the fluorescently labelled RBC were monitored by flow cytometry.Results. Flow cytometry showed that a-galactosidase (0.02 mg/mL for RBC with a haematocrit of 30%) efficiently removed Gal alpha 1,3Gal epitopes from rat erythrocytes, although small amounts of remaining Gal alpha 1,3Gal epitopes were still detected. The in vivo data demonstrated that the half-life of enzyme-treated RBC was a little shorter than that of native RBC. However, the 24-hour survival fractions of native, mock-treated and enzyme-treated RBC were virtually identical. Most importantly, the enzyme-treated RBC, like the native RBC, were still detectable 35 days after transfusion.Discussion. Our results indicate that a-glycosidase treatment had little effect on the in vivo survival kinetics of RBC. These data add further support to the feasibility of translating enzymatic conversion technology into clinical practice.